236 related articles for article (PubMed ID: 36520332)
1. Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study.
Lee CY; Lee CH; Tang HJ; Tsai HC; Yang CH; Lin YP; Wang SF; Lu PL
Infect Dis Ther; 2023 Mar; 12(3):843-861. PubMed ID: 36520332
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Wei Y; Li J; Xu R; Wen L; Deng Y; He L; Zhong H; Wang Y
Chin Med J (Engl); 2023 Nov; 136(22):2677-2685. PubMed ID: 37914678
[TBL] [Abstract][Full Text] [Related]
3. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
[TBL] [Abstract][Full Text] [Related]
4. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
[TBL] [Abstract][Full Text] [Related]
5. Immune response to ART initiation in advanced HIV infection.
Mounzer K; Brunet L; Fusco JS; McNicholl IR; Dunbar M; Sension M; McCurdy LH; Fusco GP
HIV Med; 2023 Jun; 24(6):716-726. PubMed ID: 36792544
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
8. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Acosta RK; Chen GQ; Chang S; Martin R; Wang X; Huang H; Brainard D; Collins SE; Martin H; White KL
J Antimicrob Chemother; 2021 Jul; 76(8):2153-2157. PubMed ID: 33880558
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
[TBL] [Abstract][Full Text] [Related]
10. Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study.
Lagi F; Botta A; Ciccullo A; Picarelli C; Fabbiani M; di Giambenedetto S; Borghi V; Mussini C; Bartoloni A; Sterrantino G
HIV Res Clin Pract; 2021 Aug; 22(4):96-101. PubMed ID: 34437817
[No Abstract] [Full Text] [Related]
11. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine.
Wohl D; Clarke A; Maggiolo F; Garner W; Laouri M; Martin H; Quirk E
Patient; 2018 Oct; 11(5):561-573. PubMed ID: 29956087
[TBL] [Abstract][Full Text] [Related]
12. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).
Podzamczer D; Micán R; Tiraboschi J; Portilla J; Domingo P; Llibre JM; Ribera E; Vivancos MJ; Morano L; Masiá M; Gómez C; Fanjul F; Payeras A; Inciarte A; Estrada V; Rivero A; Castro Á; Bernal E; Vinuesa D; Knobel H; Troya J; Macías J; Montero M; Sanz J; Navarro-Alcaraz A; Caicedo A; Fernández G; Martínez E; Moreno S
Open Forum Infect Dis; 2022 Mar; 9(3):ofab595. PubMed ID: 35237700
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
Expert Rev Anti Infect Ther; 2023 Nov; ():1-8. PubMed ID: 37927079
[TBL] [Abstract][Full Text] [Related]
14. Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
Mounzer K; Brunet L; Fusco JS; Mcnicholl IR; Diaz Cuervo H; Sension M; Mccurdy L; Fusco GP
Open Forum Infect Dis; 2022 Mar; 9(3):ofac018. PubMed ID: 35169590
[TBL] [Abstract][Full Text] [Related]
15. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.
Rizzardini G; Gori A; Miralles C; Olalla J; Molina JM; Raffi F; Kumar P; Antinori A; Ramgopal M; Stellbrink HJ; Das M; Chu H; Ram R; Garner W; Shao Y; Chuck SK; Piontkowsky D; Haubrich RH
AIDS; 2019 Aug; 33(10):1583-1593. PubMed ID: 31305329
[TBL] [Abstract][Full Text] [Related]
16. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Rotea-Salvo S; Martínez-Pradeda A; Fernández-Oliveira C; Giménez-Arufe V; Balboa-Barreiro V; Margusino-Framiñán L; Mena-De-Cea Á; Vázquez-Rodríguez P; Castro-Iglesias Á; López-Calvo S; Martín-Herranz I; Míguez-Rey E; Cid-Silva P
Eur J Hosp Pharm; 2023 Jul; 30(4):221-226. PubMed ID: 34649965
[TBL] [Abstract][Full Text] [Related]
17. Correction to: Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study.
Lee CY; Lee CH; Tang HJ; Tsai HC; Yang CH; Lin YP; Wang SF; Lu PL
Infect Dis Ther; 2023 Mar; 12(3):863-869. PubMed ID: 36795305
[No Abstract] [Full Text] [Related]
18. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
[TBL] [Abstract][Full Text] [Related]
20. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
